JO3377B1 - مشتقات بيريدينيل وبيريدينيل مندمج - Google Patents

مشتقات بيريدينيل وبيريدينيل مندمج

Info

Publication number
JO3377B1
JO3377B1 JOP/2014/0070A JOP20140070A JO3377B1 JO 3377 B1 JO3377 B1 JO 3377B1 JO P20140070 A JOP20140070 A JO P20140070A JO 3377 B1 JO3377 B1 JO 3377B1
Authority
JO
Jordan
Prior art keywords
pyridinyl
fused
formula
triazolone derivatives
compounds
Prior art date
Application number
JOP/2014/0070A
Other languages
English (en)
Inventor
John David Lawson
Phong H Vu
Christopher Smith
Mark Sabat
Nicholas Scorah
Haixia Wang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3377B1 publication Critical patent/JO3377B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

يتعلق الاختراع الحالي بمركبات من الصيغة 1،أو ملح مقبول دوائيا من ذلك، حيث يكون R1، R2، R3، وR4 كما تحدد في المواصفة. يتعلق هذا الاكتشاف أيضا بمواد وطرق لتحضير مركبات من الصيغة 1، بتركيبات دوائية تحتويها، وبالاستخدام لمعالجة تفاعلات حساسية مفرطة من النوع I، أمراض مناعة ذاتية، اضطرابات التهابية، سرطان، واضطرابات انقسامية غير خبيثة وحالات أخرى مصاحبة مع BTK.
JOP/2014/0070A 2013-03-11 2014-03-05 مشتقات بيريدينيل وبيريدينيل مندمج JO3377B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11

Publications (1)

Publication Number Publication Date
JO3377B1 true JO3377B1 (ar) 2019-03-13

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0070A JO3377B1 (ar) 2013-03-11 2014-03-05 مشتقات بيريدينيل وبيريدينيل مندمج

Country Status (42)

Country Link
US (4) US9402841B2 (ar)
EP (2) EP2970202B1 (ar)
JP (2) JP6271700B2 (ar)
KR (1) KR102300612B1 (ar)
CN (1) CN105121427B (ar)
AP (1) AP2015008646A0 (ar)
AR (1) AR095198A1 (ar)
AU (1) AU2014249248B2 (ar)
BR (1) BR112015020264B1 (ar)
CA (1) CA2899948C (ar)
CL (1) CL2015002370A1 (ar)
CR (1) CR20150470A (ar)
CY (1) CY1119356T1 (ar)
DK (1) DK2970202T3 (ar)
DO (1) DOP2015000184A (ar)
EA (1) EA028584B1 (ar)
EC (1) ECSP15042779A (ar)
ES (2) ES2714166T3 (ar)
GE (1) GEP201706778B (ar)
HK (2) HK1220183A1 (ar)
HR (1) HRP20170622T1 (ar)
HU (1) HUE032720T2 (ar)
IL (1) IL240353B (ar)
JO (1) JO3377B1 (ar)
LT (1) LT2970202T (ar)
MA (1) MA38391B1 (ar)
ME (1) ME02693B (ar)
MX (1) MX364527B (ar)
MY (1) MY183927A (ar)
PE (1) PE20151889A1 (ar)
PH (1) PH12015502046B1 (ar)
PL (1) PL2970202T3 (ar)
PT (1) PT2970202T (ar)
RS (1) RS55879B1 (ar)
SG (1) SG11201506112QA (ar)
SI (1) SI2970202T1 (ar)
TN (1) TN2015000342A1 (ar)
TW (1) TWI637950B (ar)
UA (1) UA114944C2 (ar)
UY (1) UY35376A (ar)
WO (1) WO2014164558A1 (ar)
ZA (1) ZA201505996B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361815B (es) 2012-09-10 2018-12-17 Principia Biopharma Inc Compuestos pirazolopirimidinicos como inhibidores de cinasas.
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
SG11201606858RA (en) 2014-02-21 2016-09-29 Principia Biopharma Inc Salts and solid form of a btk inhibitor
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
MX2017007973A (es) * 2014-12-18 2018-02-09 Principia Biopharma Inc Tratamiento de penfigo.
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
PL3394045T3 (pl) * 2015-12-24 2021-09-27 Takeda Pharmaceutical Company Limited Kokryształ, sposób jego wytwarzania i lek zawierający kokryształ
EP3402503B1 (en) * 2016-01-13 2020-10-21 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
JP7305352B2 (ja) * 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220193041A1 (en) * 2019-04-02 2022-06-23 Yonsei University, University - Industry Foundation (UIF) Novel compound and method for preventing or treating of respiratory diseases comprising the same as an active ingredient
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3185469A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002512216A (ja) 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート Ｂｔｋインヒビターならびにその同定方法および使用方法
AU2001292670A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007087068A2 (en) 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
EP2035396B1 (en) * 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2007263084A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
ATE531263T1 (de) 2006-09-22 2011-11-15 Pharmacyclics Inc Hemmer der bruton-tyrosinkinase
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
NZ586916A (en) 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
CA2728016C (en) 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es) 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
US8497265B2 (en) 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
JP5947307B2 (ja) 2010-10-20 2016-07-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド
EP2637816A4 (en) 2010-11-10 2017-07-26 Stc.Unm Aerosol reduction/expansion synthesis (a-res) for zero valent metal particles
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
UY35376A (es) 2014-10-31
MY183927A (en) 2021-03-17
AU2014249248B2 (en) 2017-08-17
KR102300612B1 (ko) 2021-09-09
HK1220183A1 (zh) 2017-04-28
ES2624439T3 (es) 2017-07-14
CY1119356T1 (el) 2018-02-14
SG11201506112QA (en) 2015-09-29
RS55879B1 (sr) 2017-08-31
CA2899948A1 (en) 2014-10-09
TWI637950B (zh) 2018-10-11
IL240353A0 (en) 2015-09-24
US10307414B2 (en) 2019-06-04
CL2015002370A1 (es) 2016-03-11
EA201591686A1 (ru) 2015-12-30
ZA201505996B (en) 2016-11-30
HUE032720T2 (en) 2017-10-30
JP6462842B2 (ja) 2019-01-30
MA38391B1 (fr) 2018-09-28
DOP2015000184A (es) 2015-11-30
PT2970202T (pt) 2017-05-03
US9402841B2 (en) 2016-08-02
EP2970202B1 (en) 2017-02-01
TW201522328A (zh) 2015-06-16
US20140256734A1 (en) 2014-09-11
EP2970202A1 (en) 2016-01-20
MA38391A1 (fr) 2018-01-31
PH12015502046A1 (en) 2016-01-18
US20180015083A1 (en) 2018-01-18
EP3235814A1 (en) 2017-10-25
AP2015008646A0 (en) 2015-08-31
SI2970202T1 (sl) 2017-07-31
US20160310483A1 (en) 2016-10-27
DK2970202T3 (en) 2017-05-08
BR112015020264A2 (pt) 2017-07-18
CR20150470A (es) 2016-01-11
LT2970202T (lt) 2017-06-12
ECSP15042779A (es) 2017-08-31
CN105121427A (zh) 2015-12-02
UA114944C2 (uk) 2017-08-28
JP2018076357A (ja) 2018-05-17
US20190224190A1 (en) 2019-07-25
PE20151889A1 (es) 2015-12-26
TN2015000342A1 (en) 2017-01-03
AU2014249248A1 (en) 2015-08-20
MX364527B (es) 2019-04-30
BR112015020264B1 (pt) 2021-03-02
CA2899948C (en) 2021-11-16
MX2015011533A (es) 2016-02-03
PH12015502046B1 (en) 2016-01-18
JP2016512515A (ja) 2016-04-28
ME02693B (me) 2017-10-20
ES2714166T3 (es) 2019-05-27
IL240353B (en) 2018-11-29
EP3235814B1 (en) 2018-12-12
PL2970202T3 (pl) 2017-08-31
HK1245256B (zh) 2019-09-27
EA028584B1 (ru) 2017-12-29
WO2014164558A1 (en) 2014-10-09
KR20150126687A (ko) 2015-11-12
AR095198A1 (es) 2015-09-30
GEP201706778B (en) 2017-11-27
CN105121427B (zh) 2018-04-10
HRP20170622T1 (hr) 2017-06-30
NZ710852A (en) 2020-12-18
JP6271700B2 (ja) 2018-01-31
US9801872B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12015502046A1 (en) Pyridinyl and fused pyridinyl triazolone derivatives
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
MX2015012006A (es) Inhibidores de bromodominio tetraciclicos.
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MY193728A (en) Muscarinic receptor agonists
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
PH12017501134A1 (en) Fumagillol derivatives
MA40553A (fr) Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders